Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and ...

Marcedes Lewis joins Colin Cowherd to discuss the shift in the tight end position since his rookie season, along with his ...

H.C. Wainwright lowered the firm’s price target on Assertio Holdings (ASRT) to $3.50 from $4 and keeps a Buy rating on the shares following the ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

H.C. Wainwright initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $20 price target Alpha is an emerging specialty ...

REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

Analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

On Wednesday, H.C. Wainwright reiterated a Neutral rating on Cassava Sciences (NASDAQ:SAVA), following the company’s announcement of its financial and operational results for the fiscal year that ...